JP2005504522A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005504522A5 JP2005504522A5 JP2003507063A JP2003507063A JP2005504522A5 JP 2005504522 A5 JP2005504522 A5 JP 2005504522A5 JP 2003507063 A JP2003507063 A JP 2003507063A JP 2003507063 A JP2003507063 A JP 2003507063A JP 2005504522 A5 JP2005504522 A5 JP 2005504522A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- growth factor
- receptor
- antisense oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 108091034117 Oligonucleotide Proteins 0.000 claims 7
- 239000000074 antisense oligonucleotide Substances 0.000 claims 7
- 238000012230 antisense oligonucleotides Methods 0.000 claims 7
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 7
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 7
- 239000003102 growth factor Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 101000712669 Homo sapiens TGF-beta receptor type-2 Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000001246 colloidal dispersion Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 230000005934 immune activation Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/888,361 US20030064944A1 (en) | 2001-06-21 | 2001-06-21 | Antisense modulation of transforming growth factor beta receptor II expression |
| PCT/US2002/019665 WO2003000656A2 (en) | 2001-06-21 | 2002-06-19 | Antisense modulation of transforming growth factor beta receptor ii expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005504522A JP2005504522A (ja) | 2005-02-17 |
| JP2005504522A5 true JP2005504522A5 (enExample) | 2006-01-12 |
Family
ID=25393053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003507063A Pending JP2005504522A (ja) | 2001-06-21 | 2002-06-19 | トランスフォーム増殖因子β受容体ＩＩ発現のアンチセンスモジュレーション |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20030064944A1 (enExample) |
| EP (1) | EP1406915A4 (enExample) |
| JP (1) | JP2005504522A (enExample) |
| AU (1) | AU2002316318A1 (enExample) |
| WO (1) | WO2003000656A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7101543B2 (en) * | 2000-03-31 | 2006-09-05 | Novarx | Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells |
| KR20020097241A (ko) * | 2000-05-04 | 2002-12-31 | 에이브이아이 바이오파마 인코포레이티드 | 스플라이스-영역 안티센스 조성물 및 방법 |
| JP2007502284A (ja) * | 2003-08-13 | 2007-02-08 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ | ｓｉＲＮＡによるＴＧＦベータＩＩ型受容体発現のサイレンシング |
| MXPA06008964A (es) * | 2004-02-09 | 2007-02-02 | Regenion Gmbh | Inhibidores de la senalizacion de tgf-r para el tratamiento de enfermedades del snc. |
| EP1857548A1 (en) * | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Means and method for inducing exon-skipping |
| GB2440782A (en) * | 2006-08-04 | 2008-02-13 | Cesare Peschle | Uses and compositions comprising miRNAs |
| WO2008109546A2 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tgfbr gene expression and uses thereof |
| US20110171287A1 (en) * | 2007-11-05 | 2011-07-14 | Baltic Technology Develpment, Ltd. | Use of Oligonucleotides with Modified Bases as Antiviral Agents |
| WO2010013350A1 (ja) * | 2008-08-01 | 2010-02-04 | Ａｓｐｉｏｎ株式会社 | Ｓ／ｏ型経皮免疫剤 |
| PH12016502062B1 (en) * | 2014-05-01 | 2023-01-27 | Ionis Pharmaceuticals Inc | Compositions and methods for modulating complement factor b expression |
| EP3020813A1 (en) * | 2014-11-16 | 2016-05-18 | Neurovision Pharma GmbH | Antisense-oligonucleotides as inhibitors of TGF-R signaling |
| JP7307417B2 (ja) * | 2017-07-10 | 2023-07-12 | 国立大学法人大阪大学 | Ｔｄｐ－４３の発現量を調節するアンチセンスオリゴヌクレオチド及びその用途 |
| CN111788216B (zh) * | 2017-12-18 | 2023-06-23 | 森正之 | 盐泡细胞形成控制作用剂和导入了该作用剂的植物体 |
| JP7321614B2 (ja) * | 2020-02-12 | 2023-08-07 | アソキュラ・ファーマシューティカルズ・スージョウ・カンパニー，リミテッド | アンチセンスオリゴヌクレオチドおよびペンドレッド症候群を処置するためのそれらの使用 |
| AU2024233625A1 (en) | 2023-03-03 | 2025-09-18 | Arsenal Biosciences, Inc. | Systems targeting psma and ca9 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6008011A (en) * | 1991-10-31 | 1999-12-28 | Whitehead Institute For Biomedical Research | TGF-β type II receptor cDNAs |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
-
2001
- 2001-06-21 US US09/888,361 patent/US20030064944A1/en not_active Abandoned
-
2002
- 2002-06-19 EP EP02746611A patent/EP1406915A4/en not_active Withdrawn
- 2002-06-19 JP JP2003507063A patent/JP2005504522A/ja active Pending
- 2002-06-19 WO PCT/US2002/019665 patent/WO2003000656A2/en not_active Ceased
- 2002-06-19 AU AU2002316318A patent/AU2002316318A1/en not_active Abandoned
-
2003
- 2003-11-10 US US10/705,715 patent/US20040147472A1/en not_active Abandoned